Drug-induced eosinophilic pneumonia in a patient with Crohn's disease: diagnosis and treatment using fraction of exhaled nitric oxide.
- Author:
Jina YEO
1
;
Hyun Sun WOO
;
Sang Min LEE
;
Yoon Jae KIM
;
Kwang An KWON
;
Dong Kyun PARK
;
Jung Ho KIM
;
Kyoung Oh KIM
;
Jun Won CHUNG
Author Information
- Publication Type:Case Report
- Keywords: Pulmonary eosinophilia; Mesalamine; Azathioprine; Crohn disease; Nitric oxide
- MeSH: Adult; Azathioprine; Crohn Disease*; Diagnosis*; Eosinophils*; Humans; Inflammatory Bowel Diseases; Mesalamine; Nitric Oxide*; Pulmonary Eosinophilia*; Treatment Outcome
- From:Intestinal Research 2017;15(4):529-534
- CountryRepublic of Korea
- Language:English
- Abstract: Oral 5-aminosalicylic acid agents (mesalazine and sulfasalazine) and azathioprine are the mainstays of treatment for inflammatory bowel disease. Reports of pulmonary toxicity induced by oral 5-aminosalicylic acid agents or azathioprine in patients with inflammatory bowel disease are very rare; to date, only 38 cases have been reported worldwide. We, herein, report a case involving a 26-year-old man who was diagnosed with eosinophilic pneumonia after using mesalazine and azathioprine for the treatment of Crohn's disease and recovered after treatment. We also found that the fraction of exhaled nitric oxide level was elevated in this patient. After treatment, the fraction of exhaled nitric oxide level decreased and the symptoms improved. The present case shows that fraction of exhaled nitric oxide is related to the disease activity and treatment effectiveness of druginduced eosinophilic pneumonia.
